Adaptive mutability of colorectal cancers in response to targeted therapies
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
A cross-kingdom tale of drug resistance: Physicians who treat bacterial infections and those who treat cancer often face a common challenge: the development of drug resistance. It is well known that when bacteria are exposed to antibiotics, they temporarily increase their mutation rate, thus increasing the chance that a descendant antibiotic-resistant cell will arise. Russo et al. now provide evidence that cancer cells exploit a similar mechanism to ensure their survival after drug exposure (see the Perspective by Gerlinger). They found that human colorectal cancer cells treated with certain targeted therapies display a transient up-regulation of errorprone DNA polymerases and a reduction in their ability to repair DNA damage. Thus, like bacteria, cancer cells can adapt to therapeutic pressure by enhancing their mutability. Science , this issue p. 1473 ; see also p. 1458
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation may be due to a more potent treatment effect with the combination of divarasib and cetuximab imposing a stronger selective pressure and/or potentially increasing the adaptive mutability of the residual cancer cells30.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [30]
Citations
Cites
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Self-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Cited by
Liquid biopsy enters the clinic — implementation issues and future challenges
Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009
“Similarly, in colorectal carcinomas treatment with EGFR and BRAF inhibitors downregulates DNA repair pathways and upregulates error-prone polymerases in drug-tolerant persister cells, therefore increasing mutation rates and the likelihood of resistance (Russo et al., 2019).”
BackgroundIntratumoral heterogeneity in cancer progression and response to immunotherapy
Vitale, I., Shema, E., Loi, S., & Galluzzi, L. (2021) · Nature Medicine · doi:10.1038/s41591-021-01233-9 · Cited by 826
Non-genetic mechanisms of therapeutic resistance in cancer
Marine, J.-C., Dawson, S.-J., & Dawson, M. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00302-4 · Cited by 635
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604
“The origin of recurring mutagenesis is attributable to the strong apoptosis-inducing effects of TKIs, which triggers down-regulation of mismatch repair and homologous recombination DNA-repair genes, along with concomitant up-regulation of error-prone DNA polymerases [43].”
BackgroundOvercoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
“Importantly, our understanding of cancer biology and the associated hallmarks of cancer is increasing.(37,238,426,427) This, coupled with repurposing studies that apply systematic screening of the entire pharmacopoeia coupled with advanced bioinformatics, should identify new drugs and their targets.”
BackgroundEnabling Technologies for Personalized and Precision Medicine
Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517
Patient-derived xenograft models in cancer therapy: technologies and applications
Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01419-2 · Cited by 494
“Moreover, intratumor heterogeneity restrains the therapeutic effect of these therapies, and cancer cells become liable to mutate under the pressure of targeted therapy, which further intensifies cancer heterogeneity.(170) Therefore, the ensuing targeted strategies may have distinct effects on different cancer cell sub…”
BackgroundRational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Metabolic regulation of homologous recombination repair by MRE11 lactylation
Chen, Y., Wu, J., Zhai, L., Zhang, T., Yin, H., Gao, H., Zhao, F., Wang, Z., Yang, X., Jin, M., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.022 · Cited by 487
Chen, E. X., Jonker, D. J., Loree, J. M., Kennecke, H. F., Berry, S. R., Couture, F., Ahmad, C. E., Goffin, J. R., Kavan, P., Harb, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0910 · Cited by 392
Kopetz, S., Guthrie, K. A., Morris, V. K., Lenz, H.-J., Magliocco, A. M., Maru, D., Yan, Y., Lanman, R., Manyam, G., Hong, D. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01994 · Cited by 389
Treatment of Advanced Melanoma in 2020 and Beyond
Jenkins, R. W., & Fisher, D. E. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.943 · Cited by 339
“stood but may be related to alterations in multiple genes or pathways, associated with upregulation of error-prone polymerases and downregulation of DNA repair mechanisms (Russo et al., 2019).”
BackgroundSingle-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303810 · Cited by 328
Overcoming resistance to tumor-targeted and immune-targeted therapies
Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311
Persistent Cancer Cells: The Deadly Survivors
Shen, S., Vagner, S., & Robert, C. (2020) · Cell · doi:10.1016/j.cell.2020.10.027 · Cited by 304
Abedizadeh, R., Majidi, F., Khorasani, H. R., Abedi, H., & Sabour, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10158-3 · Cited by 293
“…YN968D1) and cabozantinib as VEGF pathway inhibitors; dabrafenib, sorafenib, encorafenib (LGX818), and vemurafenib (PLX4720) as BRAF inhibitors [131]; lapatinib as HER-2 targeting agent [132]; prexasertib (LY2606368) a CHK1 targeting agent (102); AMG 510 an irreversible KRASG12C inhibitor;…”
Genetic and non-genetic clonal diversity in cancer evolution
Black, J. R. M., & McGranahan, N. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00336-2 · Cited by 292
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer
Hong, J., Guo, F., Lu, S.-Y., Shen, C., Ma, D., Zhang, X., Xie, Y., Yan, T., Yu, T., Sun, T., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-322780 · Cited by 290
Cancer evolution: Darwin and beyond
Vendramin, R., Litchfield, K., & Swanton, C. (2021) · The EMBO Journal · doi:10.15252/embj.2021108389 · Cited by 252
“…findings were reported in colon cancer, whereby drug-tolerant cells were shown to temporarily down-regulate mismatch repair (MMR) and homologous recombination DNA repair genes in favour of error-prone polymerases as an adaptive response to overcome BRAF and EGFR inhibition (Russo et al , 2019).”
Mechanism, cellular functions and cancer roles of polymerase-theta-mediated DNA end joining
Ramsden, D. A., Carvajal-Garcia, J., & Gupta, G. P. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00405-2 · Cited by 207
Wang, W., Xu, H., Ye, Q., Tao, F., Wheeldon, I., Yuan, A., Hu, Y., & Wu, J. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00834-6 · Cited by 206
Cell–matrix interface regulates dormancy in human colon cancer stem cells
Ohta, Y., Fujii, M., Takahashi, S., Takano, A., Nanki, K., Matano, M., Hanyu, H., Saito, M., Shimokawa, M., Nishikori, S., et al. (2022) · Nature · doi:10.1038/s41586-022-05043-y · Cited by 207
Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance
Cui, C., Yang, J., Li, X., Liu, D., Fu, L., & Wang, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01180-y · Cited by 206
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Self-citationEmerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Pu, Y., Li, L., Peng, H., Liu, L., Heymann, D., Robert, C., Vallette, F., & Shen, S. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00815-5 · Cited by 175
“When defining DTPs, three fundamental factors should be considered:”
BackgroundTherapy-induced APOBEC3A drives evolution of persistent cancer cells
Isozaki, H., Sakhtemani, R., Abbasi, A., Nikpour, N., Stanzione, M., Oh, S., Langenbucher, A., Monroe, S., Su, W., Cabanos, H. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06303-1 · Cited by 158
Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0405 · Cited by 144
“Mice were randomized”
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy
Álvarez-Varela, A., Novellasdemunt, L., Barriga, F. M., Hernando‐Momblona, X., Cañellas-Socias, A., Cano-Crespo, S., Sevillano, M., Cortina, C., Stork, D., Morral, C., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00402-0 · Cited by 162
“e–g, Percentage of tdTomato+ from total tumor epithelial area (e), average size (f) and size distribution (g) of Mex3a-derived clones in both treated and untreated conditions; n = 192 individual metastasis (from three mice), 199 (3) and 141 (3) for non-treated conditions at d2, d46 and d117 after TAM induction, respec…”
BackgroundCharacterizing the ecological and evolutionary dynamics of cancer
Zahir, N., Sun, R., Gallahan, D., Gatenby, R. A., & Curtis, C. N. (2020) · Nature Genetics · doi:10.1038/s41588-020-0668-4 · Cited by 153
Therapeutic landscape and future direction of metastatic colorectal cancer
Bando, H., Ohtsu, A., & Yoshino, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00736-1 · Cited by 166
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
“This transient cell state involves a shift to error-prone DNA repair in lieu of highly regulated mismatch or homologous recombination pathways, thus generating microsatellite instability and DNA damage 247 .”
Mowat, C., Mosley, S. R., Namdar, A., Schiller, D., & Baker, K. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210108 · Cited by 136
Crisafulli, G., Bianchi, A. S., Lazzari, L., Pietrantonio, F., Amatu, A., Macagno, M., Barault, L., Cassingena, A., Bartolini, A., Luraghi, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1434 · Cited by 146
Self-citationHe, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01891-4 · Cited by 158
“47,48 Furthermore, multiple studies 13,49 – 51 have con fi rmed the generation of the DTP cells under drug induction, with numerous factors inducing cancer cells to transition into the DTP cells, making them a recognized potential source of drug resistance.”
BackgroundDivarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02696-8 · Cited by 144
Self-citationThe Role of Oxidative Stress in Tumorigenesis and Progression
Li, K., Deng, Z., Lei, C., Ding, X., Li, J., & Wang, C. (2024) · Cells · doi:10.3390/cells13050441 · Cited by 152
“In addition, it has been elaborated that ROS induces mutagenic break repair and the SOS response via damaging bases in DNA, then pausing the replisome and allowing the critical switch from high fidelity to error-prone DNA polymerases, which provoke more carcinogenic mutation [13,14].”
BackgroundLi, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
“At the same time, the study also pointed out that the resistance to anti-EGFR agents in cancer cells will change from temporary to irreversible as the agents last longer [153], which put forward a new thinking on the choice of the targeted agents and the design of the treatment regimens.”
BackgroundType I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B
Musella, M., Guarracino, A., Manduca, N., Galassi, C., Ruggiero, E., Potenza, A., Maccafeo, E., Manic, G., Mattiello, L., Rehim, S. S. A., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01290-3 · Cited by 129
“We took advantage of a library of pre-validated MCA-derived clones de cient for cardinal elements of the IFN-I pathway, including: (1) Ifnar1, (2) stimulator of interferon response cGAMP interactor 1 (Sting1, best known as Sting), (3) toll-”
Detection of colorectal cancer-derived exosomes based on covalent organic frameworks
Wang, M., Pan, Y., Wu, S., Sun, Z., Wang, L., Yang, J. A., Yin, Y., & Li, G. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112638 · Cited by 117
Natural Extracts for Antibacterial Applications
Chen, C., Chen, L., Mao, C., Jin, L., Wu, S., Zheng, Y., Cui, Z., Li, Z., Zhang, Y., Zhu, S., et al. (2023) · Small · doi:10.1002/smll.202306553 · Cited by 129
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111
“More recently, this cell cycle restriction was also associated with the upregulation of error-prone DNA repair mechanisms that can favor the development of full resistance [2].”
BackgroundLi, Y., Mao, T., Wang, J., Zheng, H., Hu, Z., Cao, P., Yang, S., Zhu, L., Guo, S., Zhao, X., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01082-8 · Cited by 130
“found that drugresistant cancer cells that survived EGFR inhibition exhibited reduced expression of mismatch repair (MMR) genes MLH1 and decreased expression of MSH2, MSH6, and homologous recombination (HR) repair effectors BRCA2 and RAD51, thus shifting DNA polymerase from high fidelity to low fidelity, leading to da…”
BackgroundGerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J. L., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.002 · Cited by 116
“Moreover, accumulation of DNA damage and upregulation of error-pronepolymerases (Russo et al., 2019) suggests amechanism by which persister cells can acquire resistant mutations.”
BackgroundInfluentialNoronha, A., Nataraj, N. B., Lee, J. S., Zhitomirsky, B., Oren, Y., Oster, S. K., Lindzen, M., Mukherjee, S., Will, R. D., Ghosh, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0111 · Cited by 117
“More recently, it was demonstrated that SIM was capable of propelling acquired resistance to targeted therapies (5).”
BackgroundThe role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
Caswell, D. R., Gui, P., Mayekar, M. K., Law, E. K., Pich, O., Bailey, C., Boumelha, J., Kerr, D. L., Blakely, C. M., Manabe, T., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01592-8 · Cited by 120
“Our evidence here and these emerging collective findings 5,33,80,81 suggest that endogenous drivers of mutagenesis have diverse roles that are both detrimental and beneficial to tumor evolution depending on the context of tumor pathogenesis and treatment.”
BackgroundChallenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
Mulet-Margalef, N., Linares, J., Badia-Ramentol, J., Jimeno, M., Sanz, C., Mozo, J. L. M., & Calon, A. (2023) · Cancers · doi:10.3390/cancers15041022 · Cited by 122
“Conversely, a shift from pMMR/MSS to dMMR/MSI-H phenotype has been observed upon treatment with anti-EGFR mAbs and BRAF inhibitors in preclinical models of CRC [62].”
BackgroundMTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer
Cipponi, A., Goode, D. L., Bedo, J., McCabe, M. J., Pajic, M., Croucher, D. R., Rajal, A. G., Junankar, S. R., Saunders, D. N., Lobachevsky, P., et al. (2020) · Science · doi:10.1126/science.aau8768 · Cited by 103
Targeting epigenetic regulatory machinery to overcome cancer therapy resistance
Guo, L., Lee, Y., Zhou, Y., & Huang, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.022 · Cited by 111
Yang, C., Tian, C., Hoffman, T. E., Jacobsen, N. K., & Spencer, S. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21549-x · Cited by 121
Nano-enabled colorectal cancer therapy
Pan, Q., Xi, F., Xie, L. W., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.014 · Cited by 93
Ebrahimi, N., Afshinpour, M., Fakhr, S. S., Kalkhoran, P. G., Shadman-Manesh, V., Adelian, S., Beiranvand, S., Rezaei‐Tazangi, F., Khorram, R., Hamblin, M. R., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103920 · Cited by 101
Tumour-wide RNA splicing aberrations generate actionable public neoantigens
Kwok, D. W., Stevers, N. O., Etxeberría, I., Nejo, T., Cove, M. C., Chen, L. H., Jung, J., Okada, K., Lakshmanachetty, S., Gallus, M., et al. (2025) · Nature · doi:10.1038/s41586-024-08552-0 · Cited by 116
Recurrent repeat expansions in human cancer genomes
Erwin, G. S., Gürsoy, G., Al-Abri, R., Suriyaprakash, A., Dolzhenko, E., Zhu, K., Hoerner, C. R., White, S. M., Ramirez, L., Vadlakonda, A., et al. (2022) · Nature · doi:10.1038/s41586-022-05515-1 · Cited by 90
Cancer Evolution: A Multifaceted Affair
Ciriello, G., Magnani, L., Aitken, S. J., Akkari, L., Behjati, S., Hanahan, D., Landau, D. A., López-Bigas, N., Lupiáñez, D. G., Marine, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0530 · Cited by 103
“Even more, environmental pressures and treatment can induce adaptive responses, establishing non-Darwinian evolutionary routes (10, 138).”
BackgroundMapping genomic and epigenomic evolution in cancer ecosystems
Ushijima, T., Clark, S. J., & Tan, P. B. O. (2021) · Science · doi:10.1126/science.abh1645 · Cited by 97
Cell plasticity in cancer cell populations
Shen, S., & Clairambault, J. (2020) · F1000Research · doi:10.12688/f1000research.24803.1 · Cited by 101
Oxidative Stress and Inflammation: Drivers of Tumorigenesis and Therapeutic Opportunities
Wang, M., Xiao, Y., Miao, J., Zhang, X., Liu, M., Zhu, L., Liu, H., Shen, X., Wang, J., Xie, B., et al. (2025) · Antioxidants · doi:10.3390/antiox14060735 · Cited by 124
A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer
Liu, L., Yan, L., Liao, N., Wu, W.-Q., & Shi, J. (2020) · Cancers · doi:10.3390/cancers12020352 · Cited by 90
Nie, M., Chen, N., Pang, H., Jiang, T., Jiang, W., Tian, P., Yao, L., Chen, Y., DeBerardinis, R. J., Li, W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160152 · Cited by 90
“Discussion Increasing research attention has focused on understanding the impacts of DTP cell subpopulations — which survive initial therapies via nonmutational adaptions — on the long-standing problem of cancer treatment resistance (4, 8, 9, 22).”
BackgroundParseghian, C. M., Sun, R., Woods, M. N., Napolitano, S., Lee, H. M., Alshenaifi, J. Y., Willis, J. A., Nunez, S., Raghav, K. P. S., Morris, V. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01423 · Cited by 91
“We also identified other signatures associated with HR deficiency and defects in polymerase epsilon exonuclease functions, consistent with some of the features of adaptive mutability previously shown preclinically with the downregulation of HR effectors such as BRCA2 and RAD51 and upregulation of error-prone polymeras…”
BackgroundKopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Van Cutsem, E., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03235-9 · Cited by 82
“Our findings align with reports from previous smaller studies 8–10, 31 , suggesting that targeting downstream MAPK activity or MET blockade could Adaptive mutability refers to an increased mutation rate enabling cancer cells to evade therapeutic pressure 36 .”
InfluentialDigestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 98
Mauri, G., Gori, V., Bonazzina, E. F., Amatu, A., Tosi, F., Bencardino, K. B., Ruggieri, L., Patelli, G., Arena, S., Bardelli, A., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102112 · Cited by 87
Self-citationUnderstanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Ness, B. V., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 85
“Transitioning into a state of slower proliferation and associated alterations in DNA repair processes have been shown in drug-tolerant cells (53, 54) and may contribute to the subsequent genetic evolution of drug-tolerant persister cells to fully resistant cells (10, 55).”
BackgroundLactylation in cancer: Mechanisms in tumour biology and therapeutic potentials
He, Y., Song, T., Ning, J., Wang, Z., Yin, Z., Jiang, P., Yuan, Q., Yu, W., & Fan, C. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70070 · Cited by 94
“159 160–162 Recent research has found that an enzyme called mre11, which regulates homologous recombination repair, undergoes intense lactylation mediated by the p300 enzyme.”
BackgroundMirzayans, R., & Murray, D. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041308 · Cited by 79
“Recently, Russo and colleagues [91] provided evidence suggesting that colon cancer patients undergoing targeted therapy by inhibitors of EGFR (epidermal growth factor receptor) and/or BRAF (serine/threonine-protein kinase B-Raf) might also become resistant to these treatments by a similar mechanism.”
BackgroundBrägelmann, J., Lorenz, C., Borchmann, S., Nishii, K., Wegner, J., Meder, L., Ostendorp, J., Ast, D., Heimsoeth, A., Nakasuka, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25728-8 · Cited by 84
Drug Resistance in Non-Hodgkin Lymphomas
Klener, P., & Klánová, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062081 · Cited by 80
“It has been demonstrated that DTP cells exposed to anti-tumor drugs exploit adaptive mutability (a process similar to the increased mutation rate of bacteria exposed to antibiotics), which is achieved through the down-regulation of mismatch repair and homologous recombination genes with concomitant overexpression of e…”
BackgroundRedox signaling in drug-tolerant persister cells as an emerging therapeutic target
Zhang, Z., Tan, Y., Huang, C., & Wei, X. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104483 · Cited by 76
Topham, J. T., O'Callaghan, C. J., Feilotter, H., Kennecke, H. F., Lee, Y. S., Li, W., Banks, K. C., Quinn, K., Renouf, D. J., Jonker, D. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00364 · Cited by 70
Stress-Induced Mutagenesis, Gambler Cells, and Stealth Targeting Antibiotic-Induced Evolution
Pribis, J. P., Zhai, Y., Hastings, P. J., & Rosenberg, S. M. (2022) · mBio · doi:10.1128/mbio.01074-22 · Cited by 77
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines
Zhao, W., Li, J., Chen, M.-J. M., Luo, Y., Ju, Z., Nesser, N. K., Johnson-Camacho, K., Boniface, C. T., Lawrence, Y., Pande, N. T., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.008 · Cited by 75
Russo, M., Pompei, S., Sogari, A., Corigliano, M., Crisafulli, G., Puliafito, A., Lamba, S., Erriquez, J., Bertotti, A., Gherardi, M., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01105-z · Cited by 78
“We also reasoned that resistant colonies that slowly emerged after ≥ 10 weeks of drug treatment (late-emerging resistance) in persister-containing wells could have developed drug-resistance mutations through the adaptive mutability process that we and others have observed 12,13 (Fig.”
InfluentialSelf-citationLong-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Rosano, D., Sofyalı, E., Dhiman, H., Ghirardi, C., Ivanoiu, D., Heide, T., Vingiani, A., Bertolotti, A., Pruneri, G., Canale, E., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1161 · Cited by 75
“Targeting genetically fueled evolutionary process (mutagenesis) has proven to be difficult, with standard chemotherapy possibly transiently increasing genetic heterogeneity (38).”
Borelli, B., Antoniotti, C., Carullo, M., Germani, M. M., Conca, V., & Masi, G. (2022) · Cancers · doi:10.3390/cancers14204974 · Cited by 62
“Moreover, based on the fact that combining BRAF and EGFR inhibition could induce a transient MSI-H phenotype [32], Morris et al.”
BackgroundGao, X., Qiao, X., Xing, X., Huang, J., Qian, J., Wang, Y., Zhang, Y., Zhang, X., Li, M., Cui, J., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01563 · Cited by 64
“Biochemical cue-regulated drug resistance and tolerance have been well documented (6, 7, 10).”
BackgroundNapolitano, S., Falco, V. D., Martini, G., Ciardiello, D., Martinelli, E., Corte, C. M. D., Esposito, L., Famiglietti, V., Liello, A. D., Avallone, A., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0655 · Cited by 67
Szebényi, K., Füredi, A., Bajtai, E., Sama, S. N., Csiszar, A., Gombos, B., Szabó, P. T., Grusch, M., & Szakács, G. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101007 · Cited by 66
Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?
Lu, L., Jiang, J., Zhan, M., Zhang, H., Wang, Q., Sun, S., Guo, X., Yin, H., Wei, Y., Liu, J. O., et al. (2020) · Hepatology · doi:10.1002/hep.31279 · Cited by 70
“(36) Additionally, targeted agents against epidermal growth factor receptor/B-Raf protooncogene mutations down-regulated mismatch repair (MMR) and enhanced colorectal cancer mutation.(37) These studies suggest that existing treatments are useful means to enhance neoantigen generation and expression for combination the…”
BackgroundFournier, L. S., de Geus‐Oei, L., Regge, D., Oprea‐Lager, D. E., D’Anastasi, M., Bidaut, L. M., Bäuerle, T., Lopci, E., Cappello, G., Lecouvet, F. E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.800547 · Cited by 63
“This lesion-specific response has been attributed to the emergence of drug-resistant clones and indicates that tumour heterogeneity is likely causing treatment failure (121, 122).”
BackgroundHomology-directed repair protects the replicating genome from metabolic assaults
Somyajit, K., Spies, J., Coscia, F., Kirik, U., Rask, M., Lee, J., Neelsen, K. J., Mund, A., Jensen, L. J., Paull, T. T., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.01.011 · Cited by 63
Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach
Yamamoto, H., Watanabe, Y., Maehata, T., Imai, K., & Itoh, F. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02833-z · Cited by 60
Liu, S., Jiang, A., Tang, F., Duan, M., & Li, B. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02323-9 · Cited by 77
“…to low fidelity DNA replication) by down-regulating precise DNA polymerases (POLδ, POLε), mismatch repair genes and homologous recombination pathways, as well as up-regulating specialized error-prone DNA polymerases, coordinately inducing DNA mutagenesis and microsatellite instability [49, 80, 81].”
Wu, Y., Lu, D., Jiang, Y., Jin, J., Liu, S., Chen, L., Zhang, H., Zhou, Y., Chen, H., Nagle, D. G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02237 · Cited by 52
Qu, J., Sun, Z., Chen, P., Li, D., Yan, W., Xu, Z., Hou, Y., Shen, S., Chen, P., & Wang, T. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59262 · Cited by 51
“Studies have proved that loss of MMR could impair the ability to detect DNA damage and produce more mutations in tumor cells, which makes it more possible for tumor cells to improve adaptive variability and develop resistance to chemotherapeutics [8, 10, 11].”
BackgroundHuman aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage
Zerbib, J., Ippolito, M. R., Eliezer, Y., Feudis, G. D., Reuveni, E., Kadmon, A. S., Martin, S., Viganò, S., Leor, G., Berstler, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52176-x · Cited by 54
Qiu, X., Wang, A., Wang, J., Zhang, Z., & Tao, L. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02670-y · Cited by 65
“Emerging evidence indicates that reactivation of oncogenic signaling pathways is frequently accompanied by parallel reprogramming of metabolic networks, forming a coordinated “ dual-track ” mechanism of resistance driven by signaling-metabolism crosstalk [75].”
InfluentialThe importance of Ras in drug resistance in cancer
Healy, F. M., Prior, I. A., & MacEwan, D. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15420 · Cited by 53
Angiogenesis-related non-coding RNAs and gastrointestinal cancer
Razavi, Z. S., Asgarpour, K., Mahjoubin‐Tehran, M., Rasouli, S., Khan, H. Z., Shahrzad, M. K., Hamblin, M. R., & Mirzaei, H. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.002 · Cited by 52
“Despite some successes in newer therapeutic approaches, GI cancers remain life-threatening diseases.(7,8) Considering”
BackgroundPharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
Abbotts, R., Dellomo, A. J., & Rassool, F. V. (2022) · Cancers · doi:10.3390/cancers14112640 · Cited by 57
Immunotherapy-related biomarkers: Confirmations and uncertainties
Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 71
Ali, M., Lu, M., Ang, H. X., Soderquist, R. S., Eyler, C. E., Hutchinson, H. M., Glass, C., Bassil, C. F., Lopez, O. M., Kerr, D. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abc7480 · Cited by 57
Role of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis
Andreuzzi, E., Capuano, A., Poletto, E., Pivetta, E., Fejza, A., Favero, A., Doliana, R., Cannizzaro, R., Spessotto, P., & Mongiat, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103686 · Cited by 49
“Targeted therapies, such as the use of epidermal growth factor receptor (EGFR) inhibitors, provide only partial responses and for a limited period of time [6,7], with the Kirsten-rat sarcoma 2 viral oncogene homolog (KRAS) mutation status being predictive of the response [8].”
BackgroundCancer evolution: A means by which tumors evade treatment
Zhu, X. M., Shi, L., Xu, B., & Luo, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111016 · Cited by 57
Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance
Fröhlich, F., Gerosa, L., Muhlich, J. L., & Sorger, P. K. (2023) · Molecular Systems Biology · doi:10.15252/msb.202210988 · Cited by 55
“It is thought that DNA replication may be less faithful, or DNA damage responses less effective, in adapted than drug-naïve cells, leading to accumulation of resistance mutations (Russo et al, 2019; Shaffer et al, 2017; Schuh et al, 2020).”
BackgroundTargeting TANK-binding kinase 1 (TBK1) in cancer
Revach, O., Liu, S., & Jenkins, R. W. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1826929 · Cited by 54
Nickoloff, J. A., Taylor, L., Sharma, N., & Kato, T. A. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.89 · Cited by 54
“These transient radioadaptive responses are distinct from two other types of tumor adaptative responses to therapy: adaptive (upregulated) mutagenesis, which accelerates tumor evolution, and modulation of tumor microenvironments, both of which can drive tumor resistance to radio- and chemotherapy([142,143]).”
BackgroundFreedom to err: The expanding cellular functions of translesion DNA polymerases
Paniagua, I., & Jacobs, J. J. L. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.07.008 · Cited by 50
Metadata
- Authors
- Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., Sarotto, I., Nagel, Z. D., Piett, C. G., Amatu, A., Sartore-Bianchi, A., Siena, S., Bertotti, A., Trusolino, L., Corigliano, M., Gherardi, M., Lagomarsino, M. C., Di Nicolantonio, F., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Fondazione Piemontese per la Ricerca sul Cancro Onlus (IT)
- Harvard University (US)
- University of Milan (IT)
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
- Candiolo Cancer Institute, FPO–IRCCS, Candiolo (TO) 10060, Italy.
- Corresponding author
- Russo, Mariangela
- Bardelli, Alberto
- ORCID
- Russo, Mariangela
- Crisafulli, Giovanni
- Sogari, Alberto
- Reilly, Nicole M.
- Arena, Sabrina
- Lamba, Simona
- Bartolini, Alice
- Amodio, Vito
- Magrì, Alessandro
- Novara, Luca
- Sarotto, Ivana
- Nagel, Zachary D.
- Piett, Cortt G.
- Amatu, Alessio
- Sartore-Bianchi, Andrea
- Siena, Salvatore
- Bertotti, Andrea
- Trusolino, Livio
- Corigliano, Mattia
- Gherardi, Marco
- Lagomarsino, Marco Cosentino
- Di Nicolantonio, Federica
- Bardelli, Alberto
- Venue
- Science
- Published
- 2019-12-20
- Volume
- 366
- Issue
- 6472
- Pages
- 1473-1480
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2987148655
- Cited by
- 433
- References
- 62
- Citations by year
- 2026: 41 · 2025: 55 · 2024: 60 · 2023: 70 · 2022: 76 · 2021: 72 · 2020: 57 · 2019: 2
- FWCI
- 21.60
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- H2020 Health (635342-2 MoTriColor, no. 754923 COLOSSUS)
- Ministero della Salute (Ricerca Corrente 2019 RC2019)
- Associazione Italiana per la Ricerca sul Cancro (9970 Extension program, IG. 16788, ID. 21091, ID.21091, AIRC IG 2018 - ID. 21923)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, drug resistance, targeted therapy, EGFR inhibition, BRAF inhibition, DNA mismatch repair, homologous recombination, error-prone DNA polymerases, microsatellite instability, drug-tolerant persister cells, DNA damage, patient-derived xenografts
- MeSH terms
- Adaptation, Biological, Humans, Selection, Genetic, Colorectal Neoplasms, Down-Regulation, Mutagenesis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf, DNA Mismatch Repair, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.